Already a member?
Login
Become a member
Register
Home
About
About PCSK9 Forum
Editorial Board
Mission Statement
About PCSK9
What are PCSK9 inhibitors?
Why are new treatments needed?
Which patients may benefit?
PCSK9 inhibitors in practice?
News
News
Meeting Reports
PCSK9 Forum Closed Editorial Board Meetings
Newsletter
Commentary
Hot topics
From the Editors
Slides
Trials
Videos
Resources
Free eBook
Trials
Slides by Editorial Board
Events
Videos
Webcasts
Podcasts
Links
Guidelines & Consensus Guidance
Article Archive
Contact
⇒ Main Menu
Home
About
– About PCSK9 Forum
– Editorial Board
– Mission Statement
– What are PCSK9 inhibitors?
– Why are new treatments needed?
– Which patients may benefit?
– PCSK9 inhibitors in practice?
News
– News
– Meeting Reports
– PCSK9 Forum Closed Editorial Board Meetings
Newsletter
– Hot topics
– From the Editors
Slides
Trials
Videos
Resources
– Free eBook
– Trials
– Slides by Editorial Board
– Events
– Videos
– Webcasts
– Podcasts
– Links
– Guidelines & Consensus Guidance
– Article Archive
Contact
News
News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden
New US Cholesterol Guidelines: The good, the bad and the ugly
PCSK9 inhibitors and cognition back in the news
Early and low for LDL cholesterol management post-MI
ODYSSEY OUTCOMES: Uncertainty persists about CV benefit at LDL cholesterol <25 mg/dL
VIDEO: GPs in FH care
ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?
Alirocumab safe in patients with diabetes mellitus
Latest News Updates
Home
VIDEO: Perspective on the ODYSSEY OUTCOMES Economic Study
VIDEO: Perspective on the ODYSSEY OUTCOMES Economic Study
Posted on
15 November 2018
| Posted by
Gregory G. Schwartz
| Posted in
Videos
,
American Heart Association Scientific Sessions 2018
Latest videos
VIDEO: GPs in FH care
VIDEO: New FH guidance for Australasia
VIDEO: The SAMSON Study
VIDEO: Evinacumab in refractory hypercholesterolaemia
« Back to videos
Find out more
Most popular searches
Familial Hypercholesterolaemia
Unmet Needs
Webcasts
IMPROVE-IT
TESLA
Guidelines & Guidance
Plaque
Evolocumab
LDL-cholesterol
Alirocumab
Bococizumab
Videos
TAUSSIG
Podcasts
ODYSSEY
acute coronary syndrome
LY3015014
siRNA
ebbinghaus
ALN-PCSsc
Statin
Plasma
Aortic valve stenosis
Diabetic kidney disease
Glagov
safeheart
alicr
Orion
FOURIER
dyslipidaemia
Spire
Inclisiran
Homozygous FH
CANTOS
Reveal
Anacetrapib
Acute MI
EUROASPIRE IV
cascade screening
Paedriatic FH
Toth PP
Meta-Analysis
PCSK9 Inhibitors
Kasteliein
Mutations for Familial Hypercholesterolaemia
DEFESCHE
ESC/EAS TASK FORCE ON PCSK9 INHIBITION
LDL-Targets
Imaging
Clinical Profiling
PCSK9 inhibitor approval
clinical guidance for PCSK9
Joint Task Force on Use of PCSK9 Therapy
PCSK9 inhibition
atherosclerotic cardiovascular disease
European Heart Journal
Circulation
dementia
neurocognitive function
Statin Intollerance
Muscle Symptoms
EAS Consensus Panel (SAMS)
SAMS
Glucose Level
Blood Glucose
Diabetes
PCSK9 inhibitor
diabetes risk
glucose metabolism
meta-analyses
genetic studies
statins
LDL receptor
Authors
Jan Boren
Henry Ginsberg
Gerald Watts
Frederick J. Raal
Sergio Fazio
Eric Bruckert
Robert Hegele
Raul Santos
Katherine Wilemon
Evan Stein
Lluís Masana
Bertrand Cariou
Anne Tybjaerg-Hansen
Anthony Wierzbicki
Steve Nicholls
Kausik Ray
Michel Farnier
Erik Stroes
Albert Wiegman
Dirk Blom
Sam Gidding
Jennifer Robinson
Alberto Zambon
Marina Cuchel
John Chapman
Matthew Ito
Kees Hovingh
Pablo Corral
Brian Ference
Joost Besseling
Philip Barter
Peter Lansberg
Nabil G. Seidah
Eran Leitersdorf
Raimund Erbel
Wolfgang Ramlow
Dario Neri
Chris Packard
Ulf Landmesser
Mariko Harada-Shiba
Bo Angelin
Baris Gencer
David Hare
Gunnar Karlsson
Francois Mach
Rodrigo Alonso
Jan Albert Kuivenhoven
Gregory G. Schwartz
Pushkal Garg
Samia R Toukhsati
Gaetano De Ferrari
J Wouter Jukema
Gerard Pasterkamp
Michael Szarek
Dirk Müller-Wieland
Pia Kamstrup
Erin Bohula
Børge Nordestgaard
Andreas M Zeiher
Peter Sever
Jane Stock
Pierre Amarenco